Serum macrophage migration inhibitory factor (MIF) as marker for prostate cancer

• US 7,361,474 B2
• Filed: 12/17/2003
• Issued: 04/22/2008
• Est. Priority Date: 02/24/2003
• Status: Expired due to Fees

• Current Assignee: United States Department of Veterans Affairs (Government of the United States of America)
• Original Assignee: US Department of Veterans Affairs (Government of the United States of America)
• Inventors: Siegler, Katherine Meyer
• Primary Examiner(s): Rawlings; Stephen L.
• Application Number:
  US10/644,797
• Publication Number:
  US 20040171021A1
• Time in Patent Office: 1,588 Days
• Field of Search: 435/7.23, 435/7.1, 530/350, 530/388.23, 530/388.24, 530/388.25, 530/388.8, 530/389.3, 530/389.7, 530/391.3, 436/64
• US Class Current: 435/7.1
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds
• CPC Class Codes: G01N 33/57434 of prostate

Abstract

The present invention provides methods for detecting, diagnosing or prognosticating prostate cancer by measuring the levels of macrophage migration inhibitory factor (MIF) in the serum of an individual. The assay for MIF can be an immunoassay, such as ELISA, or a nucleic assay, such as Nouthern blot. Genetic changes within MIF gene can predict patients that express high levels of MIF.

Claims

1. A method for detecting or diagnosing prostate cancer in an individual comprising the step of determining levels of macrophage migration inhibitory factor (MIF) and prostate specific antigen (PSA) in the serum of the individual;

and detecting or diagnosing prostate cancer where the serum MIF levels are greater than about 5 to about 10 ng/ml and the PSA levels are elevated, as compared to PSA levels in serum from normal, unaffected individuals.

2. The method of claim 1, wherein the determining step is accomplished by immunoassay.

3. The method of claim 2, wherein the immunoassay is an ELISA.

4. The method of claim 2, wherein the immunoassay is an immunoblot.

5. The method of claim 2, wherein the immunoassay is a protein array.

6. The method of claim 1, wherein the determining step comprises the steps of contacting the serum of the individual with a molecule that specifically binds MIF;

and detecting the presence of binding between MIF and the molecule.

7. The method of claim 6, wherein the molecule is an antibody.

8. The method of claim 7, wherein the antibody is selected from the group consisting of monoclonal antibodies and polyclonal antibodies.

9. The method of claim 6, wherein the molecule is labeled.

10. The method of claim 9, wherein the label is selected from the group consisting of biotin, fluorescent molecules, radioactive molecules, chromogenic substrates, chemiluminescent molecules, and enzymes.

11. The method of claim 1, further comprising the step of comparing the levels of MIF in the serum of the individual to the MIF levels of prostate cancer patients.